VRDNNasdaqPharmaceutical PreparationsFiscal year ends December 31

Viridian Therapeutics, Inc.\DE

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$20.80+1.77 (+9.30%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

Debt

Borrowings on the balance sheet, Jun 30, 2026

Viridian Therapeutics, Inc.\DE reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Bond issues

Individual notes and bonds outstanding

Bond-level data is not connected yet

Coupon, maturity and amount of each note will come from the debt footnote in Viridian Therapeutics, Inc.\DE's annual report. Trading prices and yields need FINRA TRACE data.

Where these numbers come from

Parsed from the XBRL in Viridian Therapeutics, Inc.\DE's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-15 reverse split on Mar 26, 2021
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is VRDN.

Revenue growth23220.3% · median 57.0%

Operating margin-569.7% · median -258.8%

Net margin-544.1% · median -195.3%

Company	Revenue	Growth
ETON	$105.60M	+81.5%
XNCR	$104.97M	-28.6%
AGIO	$98.34M	+140.6%
VRDN	$71.13M	+23220.3%
GOSS	$53.29M	+32.4%
AMLX	–	–

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 252
Held by institutions: 100.0%
Auditor: KPMG LLP
SEC CIK: 1590750

Advertisement
300 × 250